Heart failure (HFrEF, HFpEF) UK Medical PG Practice Questions and MCQs
Practice UK Medical PG questions for Heart failure (HFrEF, HFpEF). These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 1: A 61-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic stenosis with valve area $0.5\mathrm{cm}^2$. He develops syncope during exercise testing. What is the most appropriate management?
- A. Medical management
- B. Balloon aortic valvuloplasty
- C. Urgent aortic valve replacement (Correct Answer)
- D. Heart transplantation
- E. ICD insertion
Heart failure (HFrEF, HFpEF) Explanation: ***Urgent aortic valve replacement***
- The patient has **severe aortic stenosis** (valve area $0.5\mathrm{cm}^2$) and is highly symptomatic, indicated by **syncope during exercise**, which significantly increases the risk of sudden cardiac death.
- **Aortic valve replacement (AVR)** or TAVR is the definitive and urgent treatment required for symptomatic severe AS to alleviate symptoms and improve survival.
*Medical management*
- Medical therapy does not treat the underlying **fixed mechanical obstruction** of the aortic valve, making it ineffective for severe symptomatic AS.
- Relying solely on medical management in this scenario leads to a very poor prognosis due to the high risk of **sudden cardiac death**.
*Balloon aortic valvuloplasty*
- BAV is primarily a temporary measure, often used as a **bridge to AVR/TAVR** or in hemodynamically unstable patients, due to its high rate of restenosis.
- Given the patient is likely a surgical candidate, BAV is not considered the **definitive long-term solution** for severe AS.
*Heart transplantation*
- Heart transplantation is reserved for **end-stage heart failure** that is refractory to other medical and surgical options.
- The primary pathology (severe AS) is surgically addressable via AVR, making transplantation an **inappropriate** initial therapy.
*ICD insertion*
- Syncope in severe AS is typically due to **flow limitation** and **exertional hypotension** caused by the fixed obstruction, rather than primary ventricular tachyarrhythmias.
- Treating the underlying mechanical pathology with AVR resolves the cause of the syncope and the high risk of sudden death; therefore, an **ICD is not indicated**.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 2: A 57-year-old diabetic man presents with a non-healing foot ulcer for 3 months. Ankle-brachial pressure index is 0.3. What does this indicate?
- A. Normal arterial supply
- B. Mild arterial disease
- C. Moderate arterial disease
- D. Severe arterial disease (Correct Answer)
- E. Venous disease
Heart failure (HFrEF, HFpEF) Explanation: ***Severe arterial disease***
- An **Ankle-Brachial Pressure Index (ABPI)** of **0.3** indicates severely reduced blood flow to the lower extremities.
- This severe reduction in arterial supply is consistent with the patient's **non-healing foot ulcer** and diabetes, a major risk factor for peripheral arterial disease.
*Normal arterial supply*
- **Normal ABPI** values typically range from **0.90 to 1.30**, which is significantly higher than the given 0.3.
- An ABPI of 0.3 suggests profound compromise, far from normal blood flow required for tissue healing.
*Mild arterial disease*
- **Mild arterial disease** is generally indicated by an **ABPI between 0.70 and 0.90**.
- An ABPI of 0.3 is well below this range, signifying much more severe impairment of arterial flow.
*Moderate arterial disease*
- **Moderate arterial disease** corresponds to an **ABPI between 0.40 and 0.69**.
- The patient's ABPI of 0.3 is lower than this range, indicating a more critical level of arterial obstruction.
*Venous disease*
- The **ABPI** is a diagnostic tool primarily used to assess **arterial insufficiency**, not venous disease.
- While venous disease can cause ulcers, an ABPI of 0.3 specifically points to significant **peripheral arterial disease** as the underlying cause.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 3: A 55-year-old woman presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic regurgitation with LV end-systolic dimension 58mm and EF 48%. She is asymptomatic at rest. What is the most appropriate management?
- A. Medical management
- B. Aortic valve replacement (Correct Answer)
- C. ACE inhibitors and monitoring
- D. Exercise stress testing
- E. Cardiac catheterization
Heart failure (HFrEF, HFpEF) Explanation: ***Aortic valve replacement*** - The patient presents with **severe aortic regurgitation** and objective evidence of **left ventricular (LV) dysfunction** (EF 48% < 50%) and **LV dilatation** (end-systolic dimension 58mm > 50-55mm). These findings are Class I indications for **aortic valve replacement**, even in an asymptomatic patient. - Surgical intervention is crucial to prevent irreversible myocardial damage and improve long-term outcomes in chronic **severe aortic regurgitation** once these thresholds for LV impairment are met. *Medical management* - Medical management is typically reserved for patients with **mild to moderate aortic regurgitation** or those with severe AR but **preserved LV function** and no significant LV dilatation who are asymptomatic. - It does not address the underlying mechanical defect of the **aortic valve** and will not reverse the progressive LV remodeling and dysfunction. *ACE inhibitors and monitoring* - While ACE inhibitors can be considered for management of hypertension or symptomatic heart failure in some AR patients, they are not the definitive treatment for **severe aortic regurgitation** with established LV dysfunction. - **Monitoring alone** is inappropriate given the significant LV remodeling and dysfunction, which necessitate surgical intervention to prevent further irreversible damage. *Exercise stress testing* - Exercise stress testing is primarily used to unmask symptoms in **asymptomatic patients** with severe valve disease (e.g., aortic stenosis or regurgitation) and **preserved LV function** to assess their functional capacity and guide surgical timing. - In this case, the patient already has clear echocardiographic evidence of **LV dysfunction** (EF 48%) and significant **LV dilatation** (ESD 58mm), which are direct indications for surgery, rendering stress testing unnecessary for decision-making. *Cardiac catheterization* - **Cardiac catheterization** is primarily a diagnostic procedure performed to assess for **coronary artery disease** (CAD) in patients undergoing cardiac surgery, especially in older individuals or those with CAD risk factors. - It is not the definitive management for **aortic regurgitation** itself but may be a pre-operative step. The primary treatment remains valve replacement.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 4: A 53-year-old woman presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral regurgitation with flail posterior leaflet. LV function is normal but LV end-systolic dimension is 45mm. What is the most appropriate management?
- A. Medical management
- B. Mitral valve replacement
- C. Mitral valve repair (Correct Answer)
- D. Heart transplantation
- E. Balloon valvuloplasty
Heart failure (HFrEF, HFpEF) Explanation: ***Mitral valve repair***- Repair is the preferred management for **severe primary mitral regurgitation (MR)**, especially when the mechanism is degenerative (like a **flail leaflet**), as it provides better long-term survival and preserves native annular-ventricular continuity.- Surgery is mandated because the patient is **symptomatic** (dyspnea and fatigue) and meets criteria for severe MR (along with an **LVESD of 45 mm**, which is an independent indication for surgery even in asymptomatic patients with preserved LVEF).*Medical management*- Medical management (e.g., ACE inhibitors/beta-blockers) is appropriate only for **asymptomatic patients** who do not meet surgical LV dimensional or functional thresholds.- It is **insufficient** to halt the progression or reduce mortality in symptomatic severe primary MR, which requires definitive surgical correction.*Mitral valve replacement*- Replacement is reserved for valves deemed **unrepairable** due to extensive destruction, calcification, or complex pathology.- Repair is favored because it avoids the risks associated with prosthetic valves, such as lifelong **anticoagulation** (for mechanical valves) and prosthetic valve dysfunction.*Heart transplantation*- This procedure is reserved for **end-stage heart failure** (NYHA Class III/IV symptoms) that is refractory to all other medical and surgical therapies.- The patient has **normal LV function** (preserved LVEF), making transplantation completely unnecessary and inappropriate.*Balloon valvuloplasty*- This intervention is the primary treatment for severe, pliable **mitral stenosis**, most commonly due to rheumatic disease.- It is **contraindicated** in severe MR, particularly MR secondary to leaflet prolapse or flail, as it would worsen the severity of the regurgitation.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 5: A 56-year-old man presents with progressive dyspnea and bilateral ankle swelling. Echocardiogram shows severe aortic stenosis with valve area $0.5\mathrm{cm}^2$ and mean gradient 60 mmHg. He has multiple comorbidities making him high surgical risk. What is the most appropriate treatment?
- A. Medical management only
- B. Balloon aortic valvuloplasty
- C. Transcatheter aortic valve replacement (Correct Answer)
- D. Surgical aortic valve replacement
- E. Heart transplantation
Heart failure (HFrEF, HFpEF) Explanation: ***Transcatheter aortic valve replacement***
- The patient has **symptomatic severe aortic stenosis** (dyspnea, ankle swelling, valve area $0.5\mathrm{cm}^2$, mean gradient 60 mmHg) and is classified as **high surgical risk** due to multiple comorbidities.
- **TAVR** is the definitive, less invasive treatment of choice for severe symptomatic aortic stenosis in patients judged to be at high or prohibitive risk for standard **surgical aortic valve replacement (SAVR)**.
*Medical management only*
- Medical therapy (e.g., diuretics) offers only temporary symptomatic relief and does not alter the poor prognosis of severe symptomatic AS, which has a mean survival of 2-3 years without intervention.
- Attempting **medical management** alone in this critical setting is inappropriate given the high risk of sudden death and the availability of effective interventional options like TAVR.
*Balloon aortic valvuloplasty*
- **BAV** provides temporary symptomatic relief but is not a durable solution for degenerative severe AS, as rapid restenosis typically occurs.
- It is primarily used as a **bridge to definitive therapy (TAVR/SAVR)** in hemodynamically unstable patients or before urgent non-cardiac surgery.
*Surgical aortic valve replacement*
- **SAVR** is the gold standard intervention for severe AS in low-to-intermediate risk patients but is explicitly contraindicated here due to the patient's **high surgical risk** profile.
- Proceeding with SAVR in this patient population is associated with significantly higher rates of morbidity and mortality compared to TAVR.
*Heart transplantation*
- **Heart transplantation** is reserved for end-stage heart failure refractory to all other medical, surgical, and interventional therapies, not as a primary treatment for severe aortic valve disease.
- Valve replacement (TAVR or SAVR) is necessary to address the valvular pathology and is expected to reverse or stabilize the consequences of the pressure overload.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 6: A 46-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral stenosis with valve area 0.7 cm². He is in atrial fibrillation with rapid ventricular response. What is the most appropriate initial management?
- A. Rate control with digoxin (Correct Answer)
- B. Immediate cardioversion
- C. Balloon mitral valvuloplasty
- D. Mitral valve replacement
- E. Anticoagulation alone
Heart failure (HFrEF, HFpEF) Explanation: ***Rate control with digoxin***- Rapid ventricular rate in **atrial fibrillation** significantly reduces **diastolic filling time**, which is crucial for adequate **left ventricular filling** in severe **mitral stenosis (MS)**.- Rate control (e.g., with rate-limiting calcium channel blockers, beta-blockers, or **digoxin** in the setting of MS, especially if associated with heart failure) is the immediate priority to alleviate acute symptoms of heart failure.*Immediate cardioversion*- Cardioversion is generally postponed until the patient is properly **anticoagulated** (due to high risk of systemic **thromboembolism**) unless the patient is **hemodynamically unstable** (e.g., shock/hypotension).- In severe MS, AF often recurs due to chronic **left atrial enlargement** and high pressure, making rate control the preferred strategy over rhythm control initially.*Balloon mitral valvuloplasty*- This is the preferred definitive treatment for symptomatic severe MS but is an invasive procedure and is not appropriate as the *initial* acute management for **AF with RVR**.- A stable patient requires rate control and anticoagulation first before determining the timing of the **structural intervention** (BMV).*Mitral valve replacement*- **Mitral valve replacement (MVR)** is a major surgical procedure reserved for patients with MS who fail percutaneous **balloon mitral valvuloplasty (BMV)** or have unfavorable valve morphology.- This is not indicated as the *initial* non-invasive step to manage acute **rate complications** in a symptomatic patient.*Anticoagulation alone*- Anticoagulation is essential management for MS complicated by AF (high **thromboembolism** risk) but does not address the acute physiological cause of **dyspnea and fatigue** (the rapid heart rate).- Ignoring the **rapid ventricular response** would leave the patient vulnerable to acute circulatory deterioration and continued pulmonary congestion.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 7: A 62-year-old man presents with progressive dyspnea and orthopnea. Chest X-ray shows cardiomegaly and pulmonary edema. Echocardiogram shows EF 25%. What is the most appropriate first medication?
- A. Furosemide
- B. Digoxin
- C. ACE inhibitor (Correct Answer)
- D. Beta-blocker
- E. Spironolactone
Heart failure (HFrEF, HFpEF) Explanation: ***ACE inhibitor***
- **ACE inhibitors** (or ARNI) are the foundational, first-line **Guideline-Directed Medical Therapy (GDMT)** for heart failure with reduced EF (**HFrEF**, EF $\le$ 40%) due to their proven mortality benefit.
- They block the **Renin-Angiotensin-Aldosterone System (RAAS)**, preventing maladaptive cardiac remodeling and reducing **afterload** and **preload**.
*Furosemide*
- While necessary for managing current acute symptoms like **pulmonary edema** and volume overload, diuretics like furosemide only provide symptomatic relief.
- They do not improve the long-term prognosis or mortality in **HFrEF** and are adjuncts to GDMT, not the first medication for foundational treatment.
*Digoxin*
- Digoxin is considered a palliative option for symptom relief in patients who remain severely symptomatic despite being on maximal doses of **ACEi/ARB/ARNI**, **beta-blocker**, and **MRA** (Spironolactone).
- It is not a prognostic agent and is associated with a narrow therapeutic index, making it unsuitable as the initial therapy.
*Beta-blocker*
- **Beta-blockers** (e.g., carvedilol, metoprolol succinate) are crucial prognostic drugs but should be initiated *after* an **ACE inhibitor**.
- They should only be started when the patient is stable and **euvolemic**, as initiating them during acute decompensation can worsen heart failure symptoms due to negative **inotropy**.
*Spironolactone*
- **Spironolactone** (a Mineralocorticoid Receptor Antagonist or **MRA**) is a prognostic medication used in HFrEF, but it is typically added as a second or third agent.
- It is reserved for patients who remain symptomatic (**NYHA Class II-IV**) despite optimal titration of **ACE inhibitor** and **beta-blocker**.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 8: A 61-year-old woman presents with progressive dyspnea and bilateral ankle swelling. Echocardiogram shows severe tricuspid regurgitation. Right heart catheterization shows mean PAP 50 mmHg. What is the most likely diagnosis?
- A. Left heart failure
- B. Pulmonary hypertension (Correct Answer)
- C. COPD
- D. Pulmonary embolism
- E. Tricuspid valve disease
Heart failure (HFrEF, HFpEF) Explanation: ***Pulmonary hypertension***
- The **mean pulmonary artery pressure (PAP) of 50 mmHg** measured by right heart catheterization is the definitive diagnostic criterion for **pulmonary hypertension**, which is defined as a mean PAP > 20 mmHg at rest.
- The **progressive dyspnea** and **bilateral ankle swelling** (signs of right heart failure) along with **severe tricuspid regurgitation** (a common consequence of right ventricular pressure overload due to PH) are direct clinical manifestations of elevated pulmonary pressures.
*Left heart failure*
- While **left heart failure (LHF)** is the most common cause of **Group 2 pulmonary hypertension**, the right heart catheterization explicitly confirms the *presence* of pulmonary hypertension, making it the most direct diagnosis based on the provided hemodynamic data.
- LHF primarily causes elevated **pulmonary capillary wedge pressure (PCWP)** due to back pressure from the left side of the heart, which would be the more specific diagnostic finding for LHF as the *primary* problem.
*COPD*
- **COPD** can lead to **Group 3 pulmonary hypertension** due to chronic hypoxia and vasoconstriction, but the question primarily focuses on the hemodynamic findings of severe PH and its consequences rather than specific lung disease features like smoking history or spirometry results.
- The clinical presentation emphasizes the cardiac manifestations of high pulmonary pressures (dyspnea, ankle swelling, severe tricuspid regurgitation) rather than primary respiratory symptoms typical of advanced COPD.
*Pulmonary embolism*
- An acute massive **pulmonary embolism** typically presents with sudden or subacute onset of dyspnea and often chest pain, which is less consistent with the patient's history of **progressive dyspnea**.
- While **chronic thromboembolic pulmonary hypertension (CTEPH)** is a form of pulmonary hypertension, the question asks for the *most likely diagnosis* given the direct finding of elevated PAP, which is pulmonary hypertension itself.
*Tricuspid valve disease*
- The **severe tricuspid regurgitation (TR)** observed is most likely *secondary* or functional, resulting from the severe right ventricular dilation and remodeling caused by the chronic pressure overload from **pulmonary hypertension**.
- Primary tricuspid valve disease would typically be the *cause* of the TR, but it would not directly explain the high **mean PAP of 50 mmHg** as the primary pathology unless it led to PH (which is less common as a primary mechanism).
Heart failure (HFrEF, HFpEF) UK Medical PG Question 9: A 67-year-old man presents with progressive dyspnea and orthopnea. Chest X-ray shows cardiomegaly and Kerley B lines. BNP is 1800 pg/mL. What does BNP level indicate?
- A. Mild heart failure
- B. Moderate heart failure (Correct Answer)
- C. Severe heart failure
- D. Acute coronary syndrome
- E. Pulmonary embolism
Heart failure (HFrEF, HFpEF) Explanation: ***Moderate heart failure***- A **BNP level of 1800 pg/mL** is highly elevated and confirms the diagnosis of acute decompensated heart failure; based on common clinical stratification, this level falls into the **moderate** severity range (often 900–1800 pg/mL).- This elevated level reflects significant **ventricular wall stress** and stretching due to volume overload, correlating strongly with the patient's clinical status (dyspnea, orthopnea, Kerley B lines).*Mild heart failure*- Mild heart failure is typically associated with BNP concentrations significantly lower than 1800 pg/mL, usually ranging between **100 to 500 pg/mL**.- Patients showing features of acute volume overload, such as **Kerley B lines** and pronounced orthopnea, rarely have BNP levels in the mild range.*Severe heart failure*- While 1800 pg/mL is very high, **severe heart failure** or decompensated end-stage disease is typically associated with BNP levels exceeding **2000 to 4000 pg/mL**, depending on the threshold used.- This threshold indicates profound biventricular dysfunction and is usually reserved for the most critical or shock states, which are higher than the patient's current measurement.*Acute coronary syndrome*- While acute myocardial infarction (a subset of ACS) can cause a secondary rise in BNP due to resulting acute heart failure, BNP's primary use is to aid in the diagnosis and staging of **heart failure**, not to diagnose ACS directly.- ACS findings are usually based on ECG changes or **troponin elevation**, whereas this clinical presentation is dominatingly characterized by signs of fluid overload.*Pulmonary embolism*- Large pulmonary embolisms can cause right heart strain and elevate BNP, but the levels are often **less predictable** and usually lower than 1800 pg/mL compared to severe biventricular failure.- The X-ray findings of **cardiomegaly** and **Kerley B lines** are highly specific indicators of pulmonary venous congestion due to left-sided heart failure, making PE an unlikely primary cause of this specific constellation of findings.
Heart failure (HFrEF, HFpEF) UK Medical PG Question 10: A 51-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic stenosis. He's high surgical risk due to comorbidities. What is the most appropriate treatment?
- A. Medical management
- B. Balloon aortic valvuloplasty
- C. Transcatheter aortic valve replacement (Correct Answer)
- D. Surgical aortic valve replacement
- E. Heart transplantation
Heart failure (HFrEF, HFpEF) Explanation: ***Transcatheter aortic valve replacement***
- **TAVR** is the preferred intervention for patients with **symptomatic severe aortic stenosis** who are at **high or prohibitive surgical risk** for traditional **Surgical Aortic Valve Replacement (SAVR)**.
- This minimally invasive approach avoids open-heart surgery and cardiopulmonary bypass, making it suitable for comorbid patients and improving symptoms and prognosis.
*Medical management*
- Medical therapy for **severe aortic stenosis** provides only limited **symptomatic relief** and does not alter the natural history or improve the poor prognosis once symptoms develop.
- Once a patient with severe AS becomes **symptomatic** (dyspnea, fatigue), definitive intervention is required, as medical management alone offers little survival benefit.
*Balloon aortic valvuloplasty*
- **Balloon aortic valvuloplasty (BAV)** is typically a temporary measure or a **bridge-to-treatment** for decompensated patients due to its high short-term risk of **restenosis**.
- It is not considered a definitive, long-term solution for severe AS in adults due to its lack of durable efficacy compared to valve replacement procedures.
*Surgical aortic valve replacement*
- **SAVR** is the traditional gold standard but requires **open-heart surgery**, carrying significant **morbidity and mortality**, especially in patients deemed **high surgical risk**.
- Current guidelines recommend **TAVR** as the preferred option for high-risk patients with symptomatic severe AS due to its less invasive nature.
*Heart transplantation*
- **Heart transplantation** is a last-resort therapy primarily indicated for refractory **end-stage heart failure** when other surgical or interventional options are exhausted or not applicable.
- For isolated, symptomatic severe aortic stenosis, replacing the valve (via TAVR or SAVR) directly addresses the primary pathology and is the appropriate first-line strategy.
More Heart failure (HFrEF, HFpEF) UK Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
